PharmaCyte Biotech, Inc.

NasdaqCM:PMCB Stock Report

Market Cap: US$16.6m

PharmaCyte Biotech Management

Management criteria checks 2/4

PharmaCyte Biotech's CEO is Josh Silverman, appointed in Oct 2022, has a tenure of 1.75 years. total yearly compensation is $197.92K, comprised of 94.7% salary and 5.3% bonuses, including company stock and options. directly owns 0.59% of the company’s shares, worth $98.01K. The average tenure of the management team and the board of directors is 5.6 years and 2.5 years respectively.

Key information

Josh Silverman

Chief executive officer

US$197.9k

Total compensation

CEO salary percentage94.7%
CEO tenure1.8yrs
CEO ownership0.6%
Management average tenure5.6yrs
Board average tenure2.5yrs

Recent management updates

Recent updates

PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business

Mar 22
PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business

PharmaCyte Biotech says CEO to step down, announces strategic review of business

Oct 07

PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors

Aug 15

Is This A Good Time To Invest In PharmaCyte?

Jan 07

PharmaCyte Biotech: Buy The 'Dump'

Aug 21

CEO Compensation Analysis

How has Josh Silverman's remuneration changed compared to PharmaCyte Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Jan 31 2024n/an/a

-US$15m

Oct 31 2023n/an/a

-US$10m

Jul 31 2023n/an/a

-US$10m

Apr 30 2023US$198kUS$188k

-US$4m

Compensation vs Market: Josh's total compensation ($USD197.92K) is below average for companies of similar size in the US market ($USD697.54K).

Compensation vs Earnings: Insufficient data to compare Josh's compensation with company performance.


CEO

Josh Silverman (54 yo)

1.8yrs

Tenure

US$197,917

Compensation

Mr. Joshua N. Silverman, also known as Josh, serves as an Independent Director at Femasys Inc. since November 21, 2023. He serves as Interim Chief Executive Officer of PharmaCyte Biotech, Inc. since Octobe...


Leadership Team

NamePositionTenureCompensationOwnership
Joshua Silverman
Interim CEO1.8yrsUS$197.92k0.59%
$ 98.0k
Carlos Trujillo
Chief Financial Officer7.3yrsUS$385.26k0.12%
$ 20.4k
Jose Iglesias
Consulting Chief Medical Officer3.9yrsno datano data
Hans-Peter Hammes
Member of Medical & Scientific Advisory Board and Consultant8.7yrsno datano data

5.6yrs

Average Tenure

66yo

Average Age

Experienced Management: PMCB's management team is seasoned and experienced (5.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Joshua Silverman
Interim CEO1.9yrsUS$197.92k0.59%
$ 98.0k
Hans-Peter Hammes
Member of Medical & Scientific Advisory Board and Consultant8.7yrsno datano data
Robert Weinstein
Independent Director1.7yrsUS$18.75k0%
$ 0
Brian Salmons
Member of Medical & Scientific Advisory Board8.2yrsno datano data
Matthias Löhr
Chairman of Medical & Scientific Advisory Board2.5yrsUS$16.76kno data
Michael Abecassis
Independent Director7yrsUS$38.80k0.033%
$ 5.5k
Wayne Walker
Independent Director1.6yrsUS$12.50k0%
$ 0
Mark Rabe
Member of Medical & Scientific Advisory Boardno datano datano data
Jonathan Schechter
Independent Director1.9yrsUS$31.25k0.59%
$ 98.0k
David Judd
Member of Medical & Scientific Advisory Board5yrsno datano data

2.5yrs

Average Tenure

64.5yo

Average Age

Experienced Board: PMCB's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.